Mumps in 123 Iranian children

Abstract

e6813th International Congress on Infectious Diseases Abstracts, Poster Presentations were: staphylococci (303), enterococci (67), streptococci (194), E. coli (141), other Enterobacteriaceae (132), H. influenzae (73), M. catarrhalis (56) and Acinetobacter (16). Interpretive criteria were those of the US-FDA as published in the product package insert.Results: Tigecycline MIC 50 and susceptibility rates among species were identical between sampled years and more potent than either tetracycline or minocycline. The MIC 90 range (mg/L)/% susceptible for ENT was 0.25-4/36-100 with lowest potency noted against Proteae. Amp-C (19-46%) and ESBL strains (4-12%) were tigecycline-susceptible (≤2 mg/L). Only 2 (E. faecalis) Gram-positive cocci (GPC; 0.3%) were tigecycline-non-susceptible at 2 mg/L. The MRSA and MR-coagulase-negative staphylococcal rates were 67 and 84%. No vancomycin-resistant enterococci and only one VISA strain was detected. H. influenzae (MIC 90 , 0.5 mg/L; 40% Bˇ-lactamase-negative ampicillin-resistant) and M. catarrhalis (MIC 90 , 0.25 mg/L) were inhibited by tigecycline, as were all Acinetobacters strains at ≤4 mg/L (bimodal MIC distribution). Tigecycline was not active against P. aeruginosa (MIC 90 , 32 mg/L).Conclusions: Using US-FDA breakpoints, tigecyclineresistant rates among Japanese isolates were nil for Enterobacteriaceae and only 0.3% for GPC. Tigecycline appears to be active against current pathogens from Japan including prevalent resistance phenotypes (extended-spectrum -lactamases, MRSA, penicillin-resistant pneumococci).